title: Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat.
abstract: OBJECTIVE
  Gouty arthritis is characterized by intense, acute inflammatory reactions that occur in response to articular deposits of monosodium urate crystals. In this study we have assessed the effects of the flavonoid, quercetin, on monosodium urate crystal-induced inflammation in rats, an experimental model for gouty arthritis.
  
  
  METHODS
  Gouty arthritis was induced by intra-articular injection of monosodium urate crystal suspension inside the ankle joint of the rat right hind limb. Circumference was assessed at 2, 4, 8, 12, 24, and 48 h after monosodium urate crystal injection. Histopathological analysis of joint synovial tissue, inflammatory mediator levels, lipid peroxidation, and antioxidant status in serum, liver and joint synovial tissue were determined in control and monosodium urate crystal-treated rats at the end of experiment.
  
  
  RESULTS
  Quercetin treatment attenuated oedema in a dose-dependent manner and decreased histological signs of acute inflammation in the treated animals. In addition, quercetin treatment suppressed leucocyte recruitment, decreased chemokine levels, decreased levels of the lipid peroxidation end-product malondialdehyde, and increased antioxidant enzyme activity in treated rats.
  
  
  CONCLUSIONS
  These results indicated that quercetin exerted a strong anti-inflammatory effect that may be useful for the treatment of acute gouty arthritis.
authors: Department of Natural Medicine, School of Pharmacy, TianJin University of Traditional Chinese Medicine, TianJin, China.
authors: Jingqun
authors: J
authors: Huang
authors: Miaozhang
authors: M
authors: Zhu
authors: Ye
authors: Y
authors: Tao
authors: Siwang
authors: S
authors: Wang
authors: Jianzong
authors: J
authors: Chen
authors: Wenjuan
authors: W
authors: Sun
authors: Shuye
authors: S
authors: Li
mesh_terms: D000818:Animals; D000843:Ankle Joint; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015210:Arthritis, Gouty / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018925:Chemokines / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy; D006074:Gout Suppressants / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D020556:Neutrophil Infiltration / Q000187:drug effects; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D011794:Quercetin / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013583:Synovial Membrane / Q000378:metabolism; D014527:Uric Acid / Q000009:adverse effects / Q000378:metabolism*
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D018925:Chemokines; D006074:Gout Suppressants; D010936:Plant Extracts; D014527:Uric Acid; D008315:Malondialdehyde; D011794:Quercetin